Holen Sie sich die Stockscreener-App
8.98
6.85%
-0.66
Schlusskurs vom Vortag:
$9.64
Offen:
$9.63
24-Stunden-Volumen:
52,974
Relative Volume:
0.42
Marktkapitalisierung:
$167.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+7.54%
1M Leistung:
+1.58%
6M Leistung:
+260.64%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.80
$9.90
1-Wochen-Bereich:
$8.29
$10.28
52-Wochen-Spanne:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Firmenname
Kalaris Therapeutics Inc
Sektor
Branche
Telefon
650-249-2727
Adresse
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.98 | 180.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-11-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-23 | Fortgesetzt | Piper Sandler | Neutral |
| 2025-05-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kalaris Therapeutics Inc Aktie (KLRS) Neueste Nachrichten
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Kalaris Therapeutics raises $50M privately - MSN
What’s the MACD signal for Kalaris Therapeutics Inc.Double Top/Bottom Patterns & High Return Capital Strategies - bollywoodhelpline.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Block Trades: Can Kalaris Therapeutics Inc weather a recessionWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Swing Trade: Is Kalaris Therapeutics Inc. affected by consumer sentimentInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
How Kalaris Therapeutics Inc. stock responds to policy changesMarket Sentiment Report & Technical Pattern Based Buy Signals - Улправда
Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - Улправда
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда
KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда
Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan
Finanzdaten der Kalaris Therapeutics Inc-Aktie (KLRS)
Es liegen keine Finanzdaten für Kalaris Therapeutics Inc (KLRS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):